secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2026-09-10T13:10:47+00:00
Accession:  0001104659-26-106567
Event type: litigation
Sentiment:  negative
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance discloses three shareholder lawsuits over Zymeworks merger, supplements proxy
--------------------------------------------------------------------------------

- Three complaints filed in NY and CA courts (Aug 25, Aug 26, Sep 2, 2026) seek to enjoin merger and allege omitted info in proxy.
- Company received 13 demand letters alleging disclosure deficiencies; denies all allegations and says no supplemental disclosure required.
- Supplemental disclosures include Lazard's outreach to 60 potential counterparties, 20 confidentiality agreements, and implied equity value range of $15.25-$16.25 per share.
- Net debt as of June 30, 2026 approx. $(385) million; fully diluted shares ~54.9M.
- Evercore to receive $7M fee upon consummation of merger; shareholder meeting set for Sept 18, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926106567/0001104659-26-106567-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926106567/tm2624960d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-106567

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer